Bucheli O, Rodrigues D, Ulbricht C, Hauser A, Eyer K
Eur J Immunol. 2025; 55(2):e202350975.
PMID: 39931760
PMC: 11811814.
DOI: 10.1002/eji.202350975.
Herb M
Antioxidants (Basel). 2024; 13(2).
PMID: 38397817
PMC: 10886416.
DOI: 10.3390/antiox13020219.
Munakata W, Ando K, Yokoyama M, Fukuhara N, Yamamoto K, Fukuhara S
Int J Hematol. 2022; 117(4):553-562.
PMID: 36576659
PMC: 10063512.
DOI: 10.1007/s12185-022-03514-6.
Pagano M, Frezzato F, Visentin A, Trentin L, Brunati A
Cancers (Basel). 2022; 14(19).
PMID: 36230804
PMC: 9564050.
DOI: 10.3390/cancers14194881.
Shim J, Jo Y, Hwang H, Lee S, Ha D, Lee J
Cell Mol Life Sci. 2022; 79(2):87.
PMID: 35067747
PMC: 11071942.
DOI: 10.1007/s00018-021-04122-z.
Bruton's Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy.
Garcia-Merino A
Cells. 2021; 10(10).
PMID: 34685540
PMC: 8534278.
DOI: 10.3390/cells10102560.
Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond.
Lue J, OConnor O, Bertoni F
Ann Lymphoma. 2021; 4:7.
PMID: 34667996
PMC: 7611845.
DOI: 10.21037/aol-20-20.
Next-generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells.
Bame E, Tang H, Burns J, Arefayene M, Michelsen K, Ma B
Clin Transl Immunology. 2021; 10(6):e1295.
PMID: 34141433
PMC: 8204096.
DOI: 10.1002/cti2.1295.
Dasatinib associated lymphadenopathy in a chronic myeloid leukemia patient: A case report.
Pilalas D, Koletsa T, Arsos G, Panselinas G, Exadaktylou P, Polychronopoulos G
Medicine (Baltimore). 2020; 99(45):e22791.
PMID: 33157925
PMC: 7647569.
DOI: 10.1097/MD.0000000000022791.
Targeting N-myristoylation for therapy of B-cell lymphomas.
Beauchamp E, Yap M, Iyer A, Perinpanayagam M, Gamma J, Vincent K
Nat Commun. 2020; 11(1):5348.
PMID: 33093447
PMC: 7582192.
DOI: 10.1038/s41467-020-18998-1.
Src Family Protein Kinase Controls the Fate of B Cells in Autoimmune Diseases.
Zhang X, Mei D, Zhang L, Wei W
Inflammation. 2020; 44(2):423-433.
PMID: 33037966
DOI: 10.1007/s10753-020-01355-1.
A multicenter, open-label, phase II study of tirabrutinib (ONO/GS-4059) in patients with Waldenström's macroglobulinemia.
Sekiguchi N, Rai S, Munakata W, Suzuki K, Handa H, Shibayama H
Cancer Sci. 2020; 111(9):3327-3337.
PMID: 32639651
PMC: 7469793.
DOI: 10.1111/cas.14561.
The Role of Syk in Inflammatory Response of Human Abdominal Aortic Aneurysm Tissue.
Kanamoto R, Aoki H, Furusho A, Otsuka H, Shintani Y, Tobinaga S
Ann Vasc Dis. 2020; 13(2):151-157.
PMID: 32595791
PMC: 7315237.
DOI: 10.3400/avd.oa.20-00009.
MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications.
de Groen R, Schrader A, Kersten M, Pals S, Vermaat J
Haematologica. 2019; 104(12):2337-2348.
PMID: 31699794
PMC: 6959184.
DOI: 10.3324/haematol.2019.227272.
cAMP- and cGMP-elevating agents inhibit GPIbα-mediated aggregation but not GPIbα-stimulated Syk activation in human platelets.
Makhoul S, Trabold K, Gambaryan S, Tenzer S, Pillitteri D, Walter U
Cell Commun Signal. 2019; 17(1):122.
PMID: 31519182
PMC: 6743169.
DOI: 10.1186/s12964-019-0428-1.
The Coordination Between B Cell Receptor Signaling and the Actin Cytoskeleton During B Cell Activation.
Li J, Yin W, Jing Y, Kang D, Yang L, Cheng J
Front Immunol. 2019; 9:3096.
PMID: 30687315
PMC: 6333714.
DOI: 10.3389/fimmu.2018.03096.
Distinct Roles for Bruton's Tyrosine Kinase in B Cell Immune Synapse Formation.
Roman-Garcia S, Merino-Cortes S, Gardeta S, de Bruijn M, Hendriks R, Carrasco Y
Front Immunol. 2018; 9:2027.
PMID: 30237801
PMC: 6136277.
DOI: 10.3389/fimmu.2018.02027.
Homogeneous BTK Occupancy Assay for Pharmacodynamic Assessment of Tirabrutinib (GS-4059/ONO-4059) Target Engagement.
Yu H, Truong H, Mitchell S, Liclican A, Gosink J, Li W
SLAS Discov. 2018; 23(9):919-929.
PMID: 30011241
PMC: 6151956.
DOI: 10.1177/2472555218786165.
Osteoimmunology.
Okamoto K, Takayanagi H
Cold Spring Harb Perspect Med. 2018; 9(1).
PMID: 29610150
PMC: 6314075.
DOI: 10.1101/cshperspect.a031245.
NF-κB Activation in Lymphoid Malignancies: Genetics, Signaling, and Targeted Therapy.
Grondona P, Bucher P, Schulze-Osthoff K, Hailfinger S, Schmitt A
Biomedicines. 2018; 6(2).
PMID: 29587428
PMC: 6027339.
DOI: 10.3390/biomedicines6020038.